A minimally invasive procedure normally used to treat liver cancer also holds promise for lung cancer patients, according to a new study.
In the study, expected to be published in the July edition of The Lancet Oncology, 88 percent of lung cancer patients responded well to treatment with percutaneous image-guided radiofrequency ablation (RFA). RFA is performed in less than an hour and is a non-surgical procedure that targets large tumors with no harm to surrounding healthy tissue. After one year, 70 percent of patients survived at least one year with few side effects; none that impaired lung function, the researchers report.
As alternative to surgery in difficult liver cancer patients, RFA has proven successful, with no negative effect on quality of life, and it requires only a short hospital stay.
...................................................
No comments:
Post a Comment